ASTM Share Price

Open 2.77 Change Price %
High 2.85 1 Day -0.02 -0.72
Low 2.76 1 Week 0.00 0.00
Close 2.77 1 Month 0.00 0.00
Volume 42450 1 Year 0.00 0.00
52 Week High 0.28
52 Week Low 0.01
ASTM Important Levels
Resistance 2 2.85
Resistance 1 2.82
Pivot 2.79
Support 1 2.72
Support 2 2.69
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
AAPL 115.59 -2.25%
AAPL 115.59 -2.25%
DELL 13.86 0.22%
SIRI 4.24 1.19%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
OGXI 0.55 48.65%
SCHS 0.12 33.33%
WRES 0.09 28.57%
LGCY 1.73 27.21%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ESMC 0.48 23.08%
CPSL 0.13 18.18%
NASDAQ USA Top Losers Stocks
LLEN 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%

Aastrom Biosciences, Inc. (NASDAQ: ASTM)

ASTM Technical Analysis 4
As on 24th Nov 2014 ASTM Share Price closed @ 2.77 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.58 & Sell for SHORT-TERM with Stoploss of 2.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
ASTM Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ASTM Other Details
Segment EQ
Market Capital 64735244.00
Sector Healthcare
Industry Biotechnology
Offical website
ASTM Address
24 Frank Lloyd Wright Drive
Ann Arbor, MI 48105
United States
Phone: 734-418-4400
Fax: 734-665-0485
ASTM Latest News
Interactive Technical Analysis Chart Aastrom Biosciences, Inc. ( ASTM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Aastrom Biosciences, Inc.
ASTM Business Profile
Aastrom Biosciences, Inc. (Aastrom), incorporated on March 24, 1989, is a development-stage company. The Company is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The Company’s cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patient’s own bone marrow, to be delivered directly to damage tissues. In March 2013, it announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Ixmyelocel-T is a patient-specific, expanded multicellular therapy developed using the Company’s, automated processing system. Ixmyelocel-T is a product derived from an adult patient’s own bone marrow but it is enhanced compared with the original bone marrow. The Company’s process enhances the patient’s bone marrow mononuclear cells by expanding the mesenchymal stromal cells and M2 anti-inflammatory macrophages while retaining many of the hematopoietic cells. These cell types, known to regulate the immune response, are important in the resolution of pathologic inflammation and tissue repair. The manufacture of its patient-specific, expanded multicellular therapies is done under current Good Manufacturing Practices (cGMP) and current Good Tissue Practices (cGTP) guidelines required by the United States Food and Drug Administration (FDA). The Company’s development programs are focused on addressing areas of high unmet medical needs in severe, chronic ischemic cardiovascular diseases. The Company operates a centralized cell manufacturing facility in Ann Arbor, Michigan.